董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Wendell Wierenga | 男 | Director | 77 | 50.46万美元 | 18.84 | 2025-11-14 |
| Muna Bhanji | 女 | Director | 62 | 52.08万美元 | 8.22 | 2025-11-14 |
| Robert A. Harrington | 男 | Director | 64 | 45.33万美元 | 7.07 | 2025-11-14 |
| James M. Daly | -- | Director | -- | 72.16万美元 | 未持股 | 2025-11-14 |
| Robert I. Blum | 男 | Director,President and Chief Executive Officer | 61 | 1188.15万美元 | 162.19 | 2025-11-14 |
| John T. Henderson | 男 | Chairman | 80 | 48.03万美元 | 25.13 | 2025-11-14 |
| B. Lynne Parshall | 女 | Director | 70 | 54.00万美元 | 5.29 | 2025-11-14 |
| Nancy J. Wysenski | 女 | Director | 67 | 50.13万美元 | 8.77 | 2025-11-14 |
| Edward M. Kaye | 男 | Director | 76 | 47.88万美元 | 17.27 | 2025-11-14 |
| Robert E. Landry | 男 | Director | 61 | 119.47万美元 | 0.14 | 2025-11-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrew M. Callos | 男 | Executive Vice President and Chief Commercial Officer | 56 | 378.76万美元 | 24.28 | 2025-11-14 |
| Sung H. Lee | 男 | Executive Vice President and Chief Financial Officer | 54 | 377.08万美元 | 0.28 | 2025-11-14 |
| Robert I. Blum | 男 | Director,President and Chief Executive Officer | 61 | 1188.15万美元 | 162.19 | 2025-11-14 |
| Fady I. Malik | 男 | Executive Vice President, Research and Development | 61 | 446.71万美元 | 50.21 | 2025-11-14 |
| Jeffrey J. Hessekiel | 男 | Executive Vice President, Chief Legal and Administrative Officer | 56 | 608.62万美元 | 未持股 | 2025-11-14 |
董事简历
中英对照 | 中文 | 英文- Wendell Wierenga
-
Wendell Wierenga于2016年9月成为董事。从2011年6月到2014年1月，Wierenga博士担任Santarus，Inc.（上市生物制药公司，2014年1月被Salix Pharmaceuticals，Inc.收购）的执行副总裁兼研究与开发。从2004年7月到2011年5月，Wierenga博士担任Ambit Biosciences Corporation and NeurocrineBiosciences，Inc.的执行副总裁、研究与开发。纳斯达克:NBIX。加入Neurocrine之前，从1999年8月到2004年6月，他担任SyrRx，Inc.的首席执行官，在那里他建立了一家早期生物技术公司，该公司于2005年被Takeda Pharmaceutical Company Limited收购。从1990年到2000年，何博士也是一名老先生。Parke Davis/Warner Lambert的研究副总裁，当时该公司被辉瑞公司收购，在此之前从1974年到1990年在Upjohn Pharmaceuticals担任多个研究职位。维伦加博士在斯坦福大学获得化学博士学位，在密歇根荷兰的希望学院获得文学学士学位。他目前是Crinetics（NASDAQ:CRNX）的董事会主席，也是Cytkinetics，Inc.（NASDAQ:CYTK）的董事会成员。最近担任Anacor Pharmaceuticals Inc.和XenoPort，Inc.的董事会成员，此前他们分别出售给辉瑞公司和Arbor Pharmaceuticals，LLC。
Wendell Wierenga became a director in September 2016. From June 2011 to January 2014, Dr. Wierenga served as Executive Vice President, Research and Development at Santarus, Inc., a public biopharmaceutical company that was acquired by Salix Pharmaceuticals, Inc. in January 2014. From July 2004 to May 2011, Dr. Wierenga served as Executive Vice President, Research and Development at Ambit Biosciences Corporation and Neurocrine Biosciences, Inc. (Nasdaq: NBIX). Prior to Neurocrine, from August 1999 to June 2004 he served as the Chief Executive Officer for Syrrx, Inc. where he built an early stage biotech company which was acquired by Takeda Pharmaceutical Company Limited in 2005. From 1990 to 2000, Dr. He also was Sr. VP of Research at Parke Davis/Warner Lambert, when it was acquired by Pfizer Inc. and prior to that held various positions in research at Upjohn Pharmaceuticals from 1974 1990. Dr. Wierenga earned his Ph.D. in chemistry from Stanford University and his B.A. from Hope College in Holland, Michigan. Dr. Wierenga is currently the chair of the Board of Directors of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) and is also a member of the Board of Directors of Cytokinetics, Inc. (Nasdaq: CYTK). He was most recently was on the Board of Directors for Anacor Pharmaceuticals Inc. and XenoPort, Inc. prior to their sales to Pfizer Inc. and Arbor Pharmaceuticals, LLC, respectively. Dr. Wierenga was selected as a director due to his industry and executive business experience. - Wendell Wierenga于2016年9月成为董事。从2011年6月到2014年1月，Wierenga博士担任Santarus，Inc.（上市生物制药公司，2014年1月被Salix Pharmaceuticals，Inc.收购）的执行副总裁兼研究与开发。从2004年7月到2011年5月，Wierenga博士担任Ambit Biosciences Corporation and NeurocrineBiosciences，Inc.的执行副总裁、研究与开发。纳斯达克:NBIX。加入Neurocrine之前，从1999年8月到2004年6月，他担任SyrRx，Inc.的首席执行官，在那里他建立了一家早期生物技术公司，该公司于2005年被Takeda Pharmaceutical Company Limited收购。从1990年到2000年，何博士也是一名老先生。Parke Davis/Warner Lambert的研究副总裁，当时该公司被辉瑞公司收购，在此之前从1974年到1990年在Upjohn Pharmaceuticals担任多个研究职位。维伦加博士在斯坦福大学获得化学博士学位，在密歇根荷兰的希望学院获得文学学士学位。他目前是Crinetics（NASDAQ:CRNX）的董事会主席，也是Cytkinetics，Inc.（NASDAQ:CYTK）的董事会成员。最近担任Anacor Pharmaceuticals Inc.和XenoPort，Inc.的董事会成员，此前他们分别出售给辉瑞公司和Arbor Pharmaceuticals，LLC。
- Wendell Wierenga became a director in September 2016. From June 2011 to January 2014, Dr. Wierenga served as Executive Vice President, Research and Development at Santarus, Inc., a public biopharmaceutical company that was acquired by Salix Pharmaceuticals, Inc. in January 2014. From July 2004 to May 2011, Dr. Wierenga served as Executive Vice President, Research and Development at Ambit Biosciences Corporation and Neurocrine Biosciences, Inc. (Nasdaq: NBIX). Prior to Neurocrine, from August 1999 to June 2004 he served as the Chief Executive Officer for Syrrx, Inc. where he built an early stage biotech company which was acquired by Takeda Pharmaceutical Company Limited in 2005. From 1990 to 2000, Dr. He also was Sr. VP of Research at Parke Davis/Warner Lambert, when it was acquired by Pfizer Inc. and prior to that held various positions in research at Upjohn Pharmaceuticals from 1974 1990. Dr. Wierenga earned his Ph.D. in chemistry from Stanford University and his B.A. from Hope College in Holland, Michigan. Dr. Wierenga is currently the chair of the Board of Directors of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) and is also a member of the Board of Directors of Cytokinetics, Inc. (Nasdaq: CYTK). He was most recently was on the Board of Directors for Anacor Pharmaceuticals Inc. and XenoPort, Inc. prior to their sales to Pfizer Inc. and Arbor Pharmaceuticals, LLC, respectively. Dr. Wierenga was selected as a director due to his industry and executive business experience.
- Muna Bhanji
-
Muna Bhanji，自2022年4月起担任Intellia Therapeutics，Inc.董事会成员。Bhanji女士是TIBA Global Access，LLC的创始人和负责人，该公司是一家自2021年1月起服务于生物制药行业的商业化和市场准入战略咨询公司。Bhanji女士此前曾在默克制药公司（“默沙东”）担任越来越多的职责，包括在美国和全球商业组织担任多个高级战略领导和运营职务，每年推动超过400 + 10亿美元的广泛药物和疫苗组合的增长。最近，Bhanji女士于2010年至2020年12月期间担任默沙东在世界各地的产品的全球市场准入和政策高级副总裁，负责为患者提供付款人报销和准入，并于2014年至2017年期间担任医院和专科特许经营高级副总裁。此外，Bhanji女士还担任默沙东全球肿瘤学和全球医院及专科商业特许经营高级副总裁。她目前在Cytokinetics，Inc.，Veracyte，Inc.和Ardelyx, Inc.的董事会任职。她还在Corus International的董事会任职。Corus International是一个由信仰组织组成的合奏，致力于世界上服务最欠缺的地区的扶贫和医疗保健的交叉领域。Bhanji女士获得了罗格斯药学院的药学学士学位和圣约瑟夫大学的工商管理硕士学位。
Muna Bhanji,has served as a member of Intellia Therapeutics, Inc. board of directors since April 2022. Ms. Bhanji is the founder and principal of TIBA Global Access, LLC, a commercialization and market access strategy consultancy serving the biopharmaceutical industry since January 2021. Ms. Bhanji previously served in roles of increasing responsibility at Merck & Co., Inc. ("Merck"), including a number of senior strategic leadership and operating roles within the U.S. and global commercial organizations driving growth across a broad portfolio of medicines and vaccines of over $40+ billion annually. Most recently, Ms. Bhanji served as the senior vice president, global market access & policy with responsibility for enabling payer reimbursement and access for patients, for Merck's products around the world from 2010 through December 2020 and as senior vice president, hospital & specialty franchises from 2014 until 2017. In addition, Ms. Bhanji served as senior vice president for global oncology and global hospital and specialty commercial franchises for Merck. She currently serves on the board of directors of Cytokinetics, Inc., Veracyte, Inc. and Ardelyx, Inc. She also serves on the board of Corus International, an ensemble of faith-based organizations working at the intersection of poverty alleviation and healthcare, in the most underserved parts of the world. Ms. Bhanji earned her B.Sc. in Pharmacy from Rutgers School of Pharmacy and an M.B.A. from St. Joseph's University. - Muna Bhanji，自2022年4月起担任Intellia Therapeutics，Inc.董事会成员。Bhanji女士是TIBA Global Access，LLC的创始人和负责人，该公司是一家自2021年1月起服务于生物制药行业的商业化和市场准入战略咨询公司。Bhanji女士此前曾在默克制药公司（“默沙东”）担任越来越多的职责，包括在美国和全球商业组织担任多个高级战略领导和运营职务，每年推动超过400 + 10亿美元的广泛药物和疫苗组合的增长。最近，Bhanji女士于2010年至2020年12月期间担任默沙东在世界各地的产品的全球市场准入和政策高级副总裁，负责为患者提供付款人报销和准入，并于2014年至2017年期间担任医院和专科特许经营高级副总裁。此外，Bhanji女士还担任默沙东全球肿瘤学和全球医院及专科商业特许经营高级副总裁。她目前在Cytokinetics，Inc.，Veracyte，Inc.和Ardelyx, Inc.的董事会任职。她还在Corus International的董事会任职。Corus International是一个由信仰组织组成的合奏，致力于世界上服务最欠缺的地区的扶贫和医疗保健的交叉领域。Bhanji女士获得了罗格斯药学院的药学学士学位和圣约瑟夫大学的工商管理硕士学位。
- Muna Bhanji,has served as a member of Intellia Therapeutics, Inc. board of directors since April 2022. Ms. Bhanji is the founder and principal of TIBA Global Access, LLC, a commercialization and market access strategy consultancy serving the biopharmaceutical industry since January 2021. Ms. Bhanji previously served in roles of increasing responsibility at Merck & Co., Inc. ("Merck"), including a number of senior strategic leadership and operating roles within the U.S. and global commercial organizations driving growth across a broad portfolio of medicines and vaccines of over $40+ billion annually. Most recently, Ms. Bhanji served as the senior vice president, global market access & policy with responsibility for enabling payer reimbursement and access for patients, for Merck's products around the world from 2010 through December 2020 and as senior vice president, hospital & specialty franchises from 2014 until 2017. In addition, Ms. Bhanji served as senior vice president for global oncology and global hospital and specialty commercial franchises for Merck. She currently serves on the board of directors of Cytokinetics, Inc., Veracyte, Inc. and Ardelyx, Inc. She also serves on the board of Corus International, an ensemble of faith-based organizations working at the intersection of poverty alleviation and healthcare, in the most underserved parts of the world. Ms. Bhanji earned her B.Sc. in Pharmacy from Rutgers School of Pharmacy and an M.B.A. from St. Joseph's University.
- Robert A. Harrington
-
Robert A. Harrington，自2022年4月起担任董事会成员。Harrington博士是一名心脏病专家，担任威尔康乃尔医学的Stephen和Suzanne Weiss院长以及康奈尔大学医学事务教务长。Harrington博士此前担任Arthur L. Bloomfield医学教授，并担任斯坦福大学医学系主任超过10年。他之前是理查德·肖恩·斯塔克（Richard Sean Stack），医学博士特聘教授，杜克大学杜克临床研究所（DCRI）主任。Harrington博士曾担任美国心脏病学会（ACC）董事会成员，目前是美国心脏协会（AHA）董事会、其科学咨询和协调委员会的成员，并担任前任主席（2019-2020年）。他曾在2013年和2014年担任AHA科学会议的主席。他是美国医师协会（AAP）和大学心脏病专家协会（AUC）的当选成员。2015年当选美国国家医学研究院/医学研究院院士。2016年，他被评为美国心脏病学会硕士。曾获2017年AHA临床研究奖、2022年AHA临床心脏病学委员会（CLCD）杰出成就奖。2022年，哈灵顿博士获得了爱尔兰心脏学会颁发的斯托克斯奖章。哈林顿博士在圣十字学院获得了英语学士学位，并在塔夫茨大学医学院获得了医学博士学位。
Robert A. Harrington,has served as a member of Board of Directors since April 2022. Dr. Harrington is a cardiologist and serves as the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. Dr. Harrington was previously the Arthur L. Bloomfield Professor of Medicine and Chair of the Department of Medicine at Stanford University for more than 10 years. He was previously the Richard Sean Stack, MD Distinguished Professor and the Director of the Duke Clinical Research Institute (DCRI) at Duke University. Dr. Harrington has served as a member of the American College of Cardiology (ACC) Board of Trustees and is currently a member of the American Heart Association's (AHA) Board of Directors, its Science Advisory and Coordinating Committee, and as a past President (2019-2020). He served as the Chair for the AHA's Scientific Sessions in 2013 and 2014. He is an elected member of the Association of American Physicians (AAP) and the Association of University Cardiologists (AUC). In 2015, he was elected to membership in the National Academy of Medicine/Institute of Medicine. In 2016, he was named a Master of the American College of Cardiology. He was awarded the AHA's Clinical Research Prize in 2017 and AHA Council on Clinical Cardiology (CLCD) Distinguished Achievement Award in 2022. In 2022, Dr. Harrington was awarded the Stokes Medal from the Irish Cardiac Society. Dr. Harrington earned a B.A. in English at the College of the Holy Cross and an M.D. from Tufts University School of Medicine. - Robert A. Harrington，自2022年4月起担任董事会成员。Harrington博士是一名心脏病专家，担任威尔康乃尔医学的Stephen和Suzanne Weiss院长以及康奈尔大学医学事务教务长。Harrington博士此前担任Arthur L. Bloomfield医学教授，并担任斯坦福大学医学系主任超过10年。他之前是理查德·肖恩·斯塔克（Richard Sean Stack），医学博士特聘教授，杜克大学杜克临床研究所（DCRI）主任。Harrington博士曾担任美国心脏病学会（ACC）董事会成员，目前是美国心脏协会（AHA）董事会、其科学咨询和协调委员会的成员，并担任前任主席（2019-2020年）。他曾在2013年和2014年担任AHA科学会议的主席。他是美国医师协会（AAP）和大学心脏病专家协会（AUC）的当选成员。2015年当选美国国家医学研究院/医学研究院院士。2016年，他被评为美国心脏病学会硕士。曾获2017年AHA临床研究奖、2022年AHA临床心脏病学委员会（CLCD）杰出成就奖。2022年，哈灵顿博士获得了爱尔兰心脏学会颁发的斯托克斯奖章。哈林顿博士在圣十字学院获得了英语学士学位，并在塔夫茨大学医学院获得了医学博士学位。
- Robert A. Harrington,has served as a member of Board of Directors since April 2022. Dr. Harrington is a cardiologist and serves as the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. Dr. Harrington was previously the Arthur L. Bloomfield Professor of Medicine and Chair of the Department of Medicine at Stanford University for more than 10 years. He was previously the Richard Sean Stack, MD Distinguished Professor and the Director of the Duke Clinical Research Institute (DCRI) at Duke University. Dr. Harrington has served as a member of the American College of Cardiology (ACC) Board of Trustees and is currently a member of the American Heart Association's (AHA) Board of Directors, its Science Advisory and Coordinating Committee, and as a past President (2019-2020). He served as the Chair for the AHA's Scientific Sessions in 2013 and 2014. He is an elected member of the Association of American Physicians (AAP) and the Association of University Cardiologists (AUC). In 2015, he was elected to membership in the National Academy of Medicine/Institute of Medicine. In 2016, he was named a Master of the American College of Cardiology. He was awarded the AHA's Clinical Research Prize in 2017 and AHA Council on Clinical Cardiology (CLCD) Distinguished Achievement Award in 2022. In 2022, Dr. Harrington was awarded the Stokes Medal from the Irish Cardiac Society. Dr. Harrington earned a B.A. in English at the College of the Holy Cross and an M.D. from Tufts University School of Medicine.
- James M. Daly
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Robert I. Blum
-
Robert I. Blum于2018年9月加入Gamida Cell Ltd.董事会，担任董事长。Blum先生自2007年1月起担任Cytokinetics公司的总裁兼首席执行官。此前，Blum先生在参与Cytokinetics公司的创立后担任其他职务。加入Cytokinetics公司之前，Blum先生曾在COR Therapeutics公司担任高级业务开发和营销职位，并在Marion Laboratories公司和Syntex公司担任各种商业和业务规划职位。他获得斯坦福大学（Stanford University）人类生物学和经济学学士学位，以及哈佛商学院（Harvard Business School）工商管理硕士学位。
Robert I. Blum,was appointed as President and Chief Executive Officer and as a member of Board of Directors in January 2007. Previous to that appointment, Mr. Blum served as President from February 2006 to January 2007. He served as Executive Vice President, Corporate Development and Commercial Operations and Chief Business Officer from September 2004 to February 2006. From January 2004 to September 2004, he served as Executive Vice President, Corporate Development and Finance and Chief Financial Officer. From October 2001 to December 2003, he served as Cytokinetics, Incorporated Senior Vice President, Corporate Development and Finance and Chief Financial Officer. From July 1998 to September 2001, Mr. Blum was Vice President, Business Development. Prior to joining in July 1998, he was Director, Marketing at COR Therapeutics, Inc. since 1996. From 1991 to 1996, he was Director, Business Development at COR Therapeutics. Prior to that, Mr. Blum performed roles of increasing responsibility in sales, marketing and other pharmaceutical business functions at Marion Laboratories, Inc. and Syntex Corporation. Mr. Blum served as Chairman of the Board of Directors of Gamida Cell Ltd. from September 2018 to March 2023. Mr. Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School. - Robert I. Blum于2018年9月加入Gamida Cell Ltd.董事会，担任董事长。Blum先生自2007年1月起担任Cytokinetics公司的总裁兼首席执行官。此前，Blum先生在参与Cytokinetics公司的创立后担任其他职务。加入Cytokinetics公司之前，Blum先生曾在COR Therapeutics公司担任高级业务开发和营销职位，并在Marion Laboratories公司和Syntex公司担任各种商业和业务规划职位。他获得斯坦福大学（Stanford University）人类生物学和经济学学士学位，以及哈佛商学院（Harvard Business School）工商管理硕士学位。
- Robert I. Blum,was appointed as President and Chief Executive Officer and as a member of Board of Directors in January 2007. Previous to that appointment, Mr. Blum served as President from February 2006 to January 2007. He served as Executive Vice President, Corporate Development and Commercial Operations and Chief Business Officer from September 2004 to February 2006. From January 2004 to September 2004, he served as Executive Vice President, Corporate Development and Finance and Chief Financial Officer. From October 2001 to December 2003, he served as Cytokinetics, Incorporated Senior Vice President, Corporate Development and Finance and Chief Financial Officer. From July 1998 to September 2001, Mr. Blum was Vice President, Business Development. Prior to joining in July 1998, he was Director, Marketing at COR Therapeutics, Inc. since 1996. From 1991 to 1996, he was Director, Business Development at COR Therapeutics. Prior to that, Mr. Blum performed roles of increasing responsibility in sales, marketing and other pharmaceutical business functions at Marion Laboratories, Inc. and Syntex Corporation. Mr. Blum served as Chairman of the Board of Directors of Gamida Cell Ltd. from September 2018 to March 2023. Mr. Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School.
- John T. Henderson
-
John T. Henderson，自2009年2月起担任董事会成员，自2022年4月起担任董事会主席。自2000年12月以来，Henderson博士一直担任制药行业的顾问，担任Futurepharm LLC的总裁。Henderson博士担任NeuroVia， Inc.的首席开发官，担任该私人控股公司的执行官，直到2018年10月。直到2000年12月退休，Henderson博士在Pfizer Inc.任职超过25年，最近担任Pfizer Pharmaceuticals Group的副总裁。Henderson博士此前曾担任Pfizer在欧洲和日本的研发副总裁级别的职位。他也是辉瑞欧洲、美国和国际制药集团的医疗副总裁。从2004年到2020年12月，Henderson博士担任Myriad Genetics， Inc.（一家医疗诊断公司）的董事会成员，包括担任主席。Henderson博士获得Edinburgh大学的科学和医学学士学位，是the Royal College of Physicians （Ed。）和the Faculty of Pharmaceutical Medicine的研究员。
John T. Henderson,has served as a member of Board of Directors since February 2009 and as Chairman of Board of Directors since April 2022. Since December 2000, Dr. Henderson has served as a consultant to the pharmaceutical industry as president of Futurepharm LLC. Dr. Henderson consulted for NeuroVia, Inc. as Chief Development Officer and was an executive officer of this privately held company until October 2018. Until his retirement in December 2000, Dr. Henderson was with Pfizer Inc. for over 25 years, most recently as a Vice President in the Pfizer Pharmaceuticals Group. Dr. Henderson previously held Vice Presidential level positions with Pfizer in Research and Development in Europe and later in Japan. He was also Vice President, Medical for Pfizer's Europe, U.S. and International Pharmaceuticals groups. Dr. Henderson has served on the Board of Directors of Myriad Genetics, Inc., a healthcare diagnostics company, from 2004 to December 2020, including as Chairman. Dr. Henderson earned his bachelor of science and medical degrees from the University of Edinburgh and is a Fellow of the Royal College of Physicians (Ed.) and the Faculty of Pharmaceutical Medicine. - John T. Henderson，自2009年2月起担任董事会成员，自2022年4月起担任董事会主席。自2000年12月以来，Henderson博士一直担任制药行业的顾问，担任Futurepharm LLC的总裁。Henderson博士担任NeuroVia， Inc.的首席开发官，担任该私人控股公司的执行官，直到2018年10月。直到2000年12月退休，Henderson博士在Pfizer Inc.任职超过25年，最近担任Pfizer Pharmaceuticals Group的副总裁。Henderson博士此前曾担任Pfizer在欧洲和日本的研发副总裁级别的职位。他也是辉瑞欧洲、美国和国际制药集团的医疗副总裁。从2004年到2020年12月，Henderson博士担任Myriad Genetics， Inc.（一家医疗诊断公司）的董事会成员，包括担任主席。Henderson博士获得Edinburgh大学的科学和医学学士学位，是the Royal College of Physicians （Ed。）和the Faculty of Pharmaceutical Medicine的研究员。
- John T. Henderson,has served as a member of Board of Directors since February 2009 and as Chairman of Board of Directors since April 2022. Since December 2000, Dr. Henderson has served as a consultant to the pharmaceutical industry as president of Futurepharm LLC. Dr. Henderson consulted for NeuroVia, Inc. as Chief Development Officer and was an executive officer of this privately held company until October 2018. Until his retirement in December 2000, Dr. Henderson was with Pfizer Inc. for over 25 years, most recently as a Vice President in the Pfizer Pharmaceuticals Group. Dr. Henderson previously held Vice Presidential level positions with Pfizer in Research and Development in Europe and later in Japan. He was also Vice President, Medical for Pfizer's Europe, U.S. and International Pharmaceuticals groups. Dr. Henderson has served on the Board of Directors of Myriad Genetics, Inc., a healthcare diagnostics company, from 2004 to December 2020, including as Chairman. Dr. Henderson earned his bachelor of science and medical degrees from the University of Edinburgh and is a Fellow of the Royal College of Physicians (Ed.) and the Faculty of Pharmaceutical Medicine.
- B. Lynne Parshall
-
B. Lynne Parshall， 2013年2月起担任董事会成员。她目前担任Ionis Pharmaceuticals， Inc.和Foghorn Therapeutics Inc.的董事会成员。Parshall女士于1991年至2017年在Ionis任职，在那里她担任过各种职务。在加入Ionis之前，她是Cooley LLP律师事务所的合伙人。Parshall女士自2021年12月起担任私营生命科学公司Repetoir Immune Medicines， Inc.的董事会成员；自2022年3月起担任私营生命科学公司Ring Therapeutics的董事会成员；自2022年8月起担任Foghorn Therapeutics的董事会成员；自2023年起担任私营公司Alltrna和Celdeara Medical的董事会成员。Parshall女士从2015年到2020年10月担任Akcea Therapeutics Inc.的董事会成员。Parshall女士是the Licensing Executives Society的成员，也是美国、加州和圣地亚哥律师协会的成员。她拥有斯坦福大学法学院的法学博士学位和哈佛大学的学士学位。
B. Lynne Parshall,has served as a member of Board of Directors since February 2013. She currently serves as a member of the Board of Directors of Ionis Pharmaceuticals, Inc. and Foghorn Therapeutics Inc. Ms. Parshall was employed at Ionis from 1991 to 2017 where she held various positions of increasing responsibility. Prior to joining Ionis, she was a partner at the law firm of Cooley LLP. Ms. Parshall has served on the Board of Directors of Repetoir Immune Medicines, Inc., a private life sciences company, since December 2021, Ring Therapeutics, a private life sciences company, since March 2022 and Foghorn Therapeutics since August 2022 and each of Alltrna and Celdeara Medical, both private companies, since 2023. Ms. Parshall served as a member of the Board of Directors of Akcea Therapeutics Inc. from 2015 to October 2020. Ms. Parshall is a member of the Licensing Executives Society and a member of the American, California and San Diego bar associations. She holds a J.D. from Stanford Law School and a B.A. from Harvard University. - B. Lynne Parshall， 2013年2月起担任董事会成员。她目前担任Ionis Pharmaceuticals， Inc.和Foghorn Therapeutics Inc.的董事会成员。Parshall女士于1991年至2017年在Ionis任职，在那里她担任过各种职务。在加入Ionis之前，她是Cooley LLP律师事务所的合伙人。Parshall女士自2021年12月起担任私营生命科学公司Repetoir Immune Medicines， Inc.的董事会成员；自2022年3月起担任私营生命科学公司Ring Therapeutics的董事会成员；自2022年8月起担任Foghorn Therapeutics的董事会成员；自2023年起担任私营公司Alltrna和Celdeara Medical的董事会成员。Parshall女士从2015年到2020年10月担任Akcea Therapeutics Inc.的董事会成员。Parshall女士是the Licensing Executives Society的成员，也是美国、加州和圣地亚哥律师协会的成员。她拥有斯坦福大学法学院的法学博士学位和哈佛大学的学士学位。
- B. Lynne Parshall,has served as a member of Board of Directors since February 2013. She currently serves as a member of the Board of Directors of Ionis Pharmaceuticals, Inc. and Foghorn Therapeutics Inc. Ms. Parshall was employed at Ionis from 1991 to 2017 where she held various positions of increasing responsibility. Prior to joining Ionis, she was a partner at the law firm of Cooley LLP. Ms. Parshall has served on the Board of Directors of Repetoir Immune Medicines, Inc., a private life sciences company, since December 2021, Ring Therapeutics, a private life sciences company, since March 2022 and Foghorn Therapeutics since August 2022 and each of Alltrna and Celdeara Medical, both private companies, since 2023. Ms. Parshall served as a member of the Board of Directors of Akcea Therapeutics Inc. from 2015 to October 2020. Ms. Parshall is a member of the Licensing Executives Society and a member of the American, California and San Diego bar associations. She holds a J.D. from Stanford Law School and a B.A. from Harvard University.
- Nancy J. Wysenski
-
Nancy J. Wysenski，Wysenski女士担任执行副总裁和首席商务官，她从2009年12月开始担任该职位。加入公司前，Wysenski女士担任远藤制药公司（Endo Pharmaceuticals）的首席运营官，这是一家1200人组成的专业制药公司，她在该公司领导了销售、营销、商业经营、供应链管理、人力资源与多个业务开发计划。在Endo任职前，Wysenski女士参与创建德国默克集团（EMD Pharmaceuticals, Inc.），她在该公司担任过多个领导职位，包括从2001年到2006年担任总裁兼首席执行官，并从1999年到2001年担任商务部副总裁。从1984年到1998年，Wysenski女士在大型制药公司担任过几个销售型职位，包括Astra Merck, Inc.的现场销售部副总裁。Wysenski女士担任北卡罗来纳中央大学（North Carolina Central University）校董会董事，并担任Reata Pharmaceuticals, Inc.的董事，这是一家私人所有的公司。她是三角研究园区（Research Triangle Park）的创始人，其为医疗界女企业家协会（Healthcare Business Women's Association）的分会。Wysenski女士在Kent State大学获得理学学士学位，并在鲍德温·华勒斯学院（Baldwin Wallace College）获得高管工商管理硕士学位。
Nancy J. Wysenski served as the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals Incorporated "Vertex" from December 2009 through June 2012. Prior to joining Vertex, Ms. Wysenski held the position of Chief Operating Officer of Endo Pharmaceuticals plc "Endo", a specialty pharmaceutical company, where she led sales, marketing, commercial operations, supply chain management, human resources and various business development initiatives. Prior to her role at Endo, Ms. Wysenski participated in the establishment of EMD Pharmaceuticals, Inc., where she held various leadership positions, including the role of President and Chief Executive Officer from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998 Ms. Wysenski held several sales-focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc. Ms. Wysenski formerly served as a director for Reata Pharmaceuticals, Inc., now a publicly-traded biopharmaceutical company, and more recently served as a director for Inovio Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from March 2015 to May 2017 Tetraphase Pharmaceuticals, Inc., formerly a publicly-traded biopharmaceutical company, from March 2014 to July 2020 and Dova Pharmaceuticals Inc., formerly a publicly-traded biopharmaceutical company, from June 2018 to November 2019. She is a founder of the Research Triangle Park chapter of the Healthcare Business Women's Association and served on the Nominating Committee and National Advisory Board of the Healthcare Businesswomen's Association. - Nancy J. Wysenski，Wysenski女士担任执行副总裁和首席商务官，她从2009年12月开始担任该职位。加入公司前，Wysenski女士担任远藤制药公司（Endo Pharmaceuticals）的首席运营官，这是一家1200人组成的专业制药公司，她在该公司领导了销售、营销、商业经营、供应链管理、人力资源与多个业务开发计划。在Endo任职前，Wysenski女士参与创建德国默克集团（EMD Pharmaceuticals, Inc.），她在该公司担任过多个领导职位，包括从2001年到2006年担任总裁兼首席执行官，并从1999年到2001年担任商务部副总裁。从1984年到1998年，Wysenski女士在大型制药公司担任过几个销售型职位，包括Astra Merck, Inc.的现场销售部副总裁。Wysenski女士担任北卡罗来纳中央大学（North Carolina Central University）校董会董事，并担任Reata Pharmaceuticals, Inc.的董事，这是一家私人所有的公司。她是三角研究园区（Research Triangle Park）的创始人，其为医疗界女企业家协会（Healthcare Business Women's Association）的分会。Wysenski女士在Kent State大学获得理学学士学位，并在鲍德温·华勒斯学院（Baldwin Wallace College）获得高管工商管理硕士学位。
- Nancy J. Wysenski served as the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals Incorporated "Vertex" from December 2009 through June 2012. Prior to joining Vertex, Ms. Wysenski held the position of Chief Operating Officer of Endo Pharmaceuticals plc "Endo", a specialty pharmaceutical company, where she led sales, marketing, commercial operations, supply chain management, human resources and various business development initiatives. Prior to her role at Endo, Ms. Wysenski participated in the establishment of EMD Pharmaceuticals, Inc., where she held various leadership positions, including the role of President and Chief Executive Officer from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998 Ms. Wysenski held several sales-focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc. Ms. Wysenski formerly served as a director for Reata Pharmaceuticals, Inc., now a publicly-traded biopharmaceutical company, and more recently served as a director for Inovio Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from March 2015 to May 2017 Tetraphase Pharmaceuticals, Inc., formerly a publicly-traded biopharmaceutical company, from March 2014 to July 2020 and Dova Pharmaceuticals Inc., formerly a publicly-traded biopharmaceutical company, from June 2018 to November 2019. She is a founder of the Research Triangle Park chapter of the Healthcare Business Women's Association and served on the Nominating Committee and National Advisory Board of the Healthcare Businesswomen's Association.
- Edward M. Kaye
-
Edward M. Kaye，自2017年10月起担任Stoke Therapeutics, Inc.董事会成员，还于2017年10月至2025年3月期间担任Stoke Therapeutics, Inc.首席执行官。他从医疗研究和药物开发公司Sarepta Therapeutics, Inc.加入Stoke Therapeutics，曾于2016年9月至2017年7月担任总裁兼首席执行官，2015年4月至2016年9月担任临时首席执行官，2011年6月至2017年3月担任首席医疗官。从2001年到2011年，Kaye博士曾在生物技术公司Genzyme Corporation担任多个职位，包括最近担任集团临床开发副总裁。此前，Kaye博士曾担任Philadelphia儿童医院生化遗传学主任、St. Christopher儿童医院神经内科主任，以及Massachusetts General Hospital and Tufts University Medical Center的研究人员。Kaye医生目前在波士顿儿童医院担任神经学顾问。Kaye博士还是一家上市生物制药公司Cytokinetics公司、一家上市生物技术公司Avidity Biosciences公司以及一家私营非营利性生命科学行业组织Massachusetts Biotechnology Council的董事会成员。Kaye博士拥有Loyola大学的生物学/化学学士学位和Loyola大学Stritch医学院的医学博士学位。
Edward M. Kaye,has served as a member of Stoke Therapeutics, Inc. Board of Directors since October 2017 and also served as Stoke Therapeutics, Inc. Chief Executive Officer from October 2017 to March 2025. He joined Stoke Therapeutics, Inc. from Sarepta Therapeutics, Inc., a medical research and drug development company, where he served as President and Chief Executive Officer from September 2016 to July 2017, Interim Chief Executive Officer from April 2015 to September 2016 and Chief Medical Officer from June 2011 to March 2017. From 2001 to 2011, Dr. Kaye served in various positions at Genzyme Corporation, a biotechnology company, including most recently as Group Vice President of Clinical Development. Previously, Dr. Kaye served as Chief of Biochemical Genetics at Children's Hospital of Philadelphia, Chief of Neurology at St. Christopher's Hospital for Children, and as a member of the research staff at Massachusetts General Hospital and Tufts University Medical Center. Dr. Kaye currently serves as a Neurological Consultant at the Children's Hospital of Boston. Dr. Kaye is also a member of the boards of directors of Cytokinetics, Inc., a public biopharmaceutical company, Avidity Biosciences, Inc. a public biotechnology company, and the Massachusetts Biotechnology Council, a private non-profit life sciences industry organization. Dr. Kaye holds a B.S. in Biology/Chemistry from Loyola University and a M.D. from the Loyola University Stritch School of Medicine. - Edward M. Kaye，自2017年10月起担任Stoke Therapeutics, Inc.董事会成员，还于2017年10月至2025年3月期间担任Stoke Therapeutics, Inc.首席执行官。他从医疗研究和药物开发公司Sarepta Therapeutics, Inc.加入Stoke Therapeutics，曾于2016年9月至2017年7月担任总裁兼首席执行官，2015年4月至2016年9月担任临时首席执行官，2011年6月至2017年3月担任首席医疗官。从2001年到2011年，Kaye博士曾在生物技术公司Genzyme Corporation担任多个职位，包括最近担任集团临床开发副总裁。此前，Kaye博士曾担任Philadelphia儿童医院生化遗传学主任、St. Christopher儿童医院神经内科主任，以及Massachusetts General Hospital and Tufts University Medical Center的研究人员。Kaye医生目前在波士顿儿童医院担任神经学顾问。Kaye博士还是一家上市生物制药公司Cytokinetics公司、一家上市生物技术公司Avidity Biosciences公司以及一家私营非营利性生命科学行业组织Massachusetts Biotechnology Council的董事会成员。Kaye博士拥有Loyola大学的生物学/化学学士学位和Loyola大学Stritch医学院的医学博士学位。
- Edward M. Kaye,has served as a member of Stoke Therapeutics, Inc. Board of Directors since October 2017 and also served as Stoke Therapeutics, Inc. Chief Executive Officer from October 2017 to March 2025. He joined Stoke Therapeutics, Inc. from Sarepta Therapeutics, Inc., a medical research and drug development company, where he served as President and Chief Executive Officer from September 2016 to July 2017, Interim Chief Executive Officer from April 2015 to September 2016 and Chief Medical Officer from June 2011 to March 2017. From 2001 to 2011, Dr. Kaye served in various positions at Genzyme Corporation, a biotechnology company, including most recently as Group Vice President of Clinical Development. Previously, Dr. Kaye served as Chief of Biochemical Genetics at Children's Hospital of Philadelphia, Chief of Neurology at St. Christopher's Hospital for Children, and as a member of the research staff at Massachusetts General Hospital and Tufts University Medical Center. Dr. Kaye currently serves as a Neurological Consultant at the Children's Hospital of Boston. Dr. Kaye is also a member of the boards of directors of Cytokinetics, Inc., a public biopharmaceutical company, Avidity Biosciences, Inc. a public biotechnology company, and the Massachusetts Biotechnology Council, a private non-profit life sciences industry organization. Dr. Kaye holds a B.S. in Biology/Chemistry from Loyola University and a M.D. from the Loyola University Stritch School of Medicine.
- Robert E. Landry
-
Robert E. Landry，自2019年1月起担任财务执行副总裁，2013年10月起担任首席财务官。2013年9月至2018年12月，他担任财务高级副总裁。此前，他曾担任Pfizer Inc.的高级副总裁兼财务主管（从2012年10月到2013年8月），以及Pfizer的多元化业务财务高级副总裁（从2009年10月到2012年10月）。在此之前，Landry先生在Wyeth担任多个职位，该公司于2009年10月被辉瑞公司收购，2007年至2009年担任财务主管和首席公司官，2006年至2007年担任惠氏澳大利亚分公司的药品营销和销售总监，2004年至2006年担任惠氏澳大利亚和新西兰分公司的首席财务官。Landry先生拥有圣母大学会计学学士学位。
Robert E. Landry has served as a member of Board of Directors since Augt 2025. Mr. Landry served as the Executive Vice President and Chief Financial Officer at Regeneron Pharmaceuticals, Inc., from September 2013 to January 2024. Prior to his time at Regeneron, Mr. Landry served from January 1988 to Augt 2013 as the Senior Vice President, Treasurer, Senior Vice President, Finance, and in other vario corporate roles at Pfizer (formerly Wyeth). Mr. Landry started his career at Coopers & Lybrand, now PricewaterhoeCoopers LLP. Mr. Landry also currently serves on the board of directors of Cytokinetics, Inc., a late stage biopharmaceutical company. Mr. Landry is a Certified Public Accountant in New York (inactive) and attended the University of Notre Dame, where he earned a B.B.A. in accounting in 1986. - Robert E. Landry，自2019年1月起担任财务执行副总裁，2013年10月起担任首席财务官。2013年9月至2018年12月，他担任财务高级副总裁。此前，他曾担任Pfizer Inc.的高级副总裁兼财务主管（从2012年10月到2013年8月），以及Pfizer的多元化业务财务高级副总裁（从2009年10月到2012年10月）。在此之前，Landry先生在Wyeth担任多个职位，该公司于2009年10月被辉瑞公司收购，2007年至2009年担任财务主管和首席公司官，2006年至2007年担任惠氏澳大利亚分公司的药品营销和销售总监，2004年至2006年担任惠氏澳大利亚和新西兰分公司的首席财务官。Landry先生拥有圣母大学会计学学士学位。
- Robert E. Landry has served as a member of Board of Directors since Augt 2025. Mr. Landry served as the Executive Vice President and Chief Financial Officer at Regeneron Pharmaceuticals, Inc., from September 2013 to January 2024. Prior to his time at Regeneron, Mr. Landry served from January 1988 to Augt 2013 as the Senior Vice President, Treasurer, Senior Vice President, Finance, and in other vario corporate roles at Pfizer (formerly Wyeth). Mr. Landry started his career at Coopers & Lybrand, now PricewaterhoeCoopers LLP. Mr. Landry also currently serves on the board of directors of Cytokinetics, Inc., a late stage biopharmaceutical company. Mr. Landry is a Certified Public Accountant in New York (inactive) and attended the University of Notre Dame, where he earned a B.B.A. in accounting in 1986.
高管简历
中英对照 | 中文 | 英文- Andrew M. Callos
Andrew M. Callos，自2021年3月起担任执行副总裁、首席商务官。在加入Cytokinetics之前，Andrew在辉瑞和惠氏制药公司工作了20多年，担任的职责越来越多，负责监督美国和国际制药特许经营权，最近在辉瑞担任Upjohn业务部门北美区域总裁兼总经理。在担任此职务之前，在辉瑞工作的11年多时间里，他担任过多个领导职务，包括美国心脏病学和代谢营销副总裁，在那里他领导了Eliquis在美国的商业化工作，副总裁兼炎症营销欧洲负责人以及全球商业开发罕见病副总裁。在加入辉瑞之前，Callos先生在惠氏制药工作了10多年，在业务规划与分析领域担任过多个职务，最终担任多个产品的营销副总裁。卡洛斯先生开始了他在埃森哲担任咨询经理职业生涯的前七年。Callos先生拥有德雷克塞尔大学商业和工程学士学位。
Andrew M. Callos,has served as Executive Vice President, Chief Commercial Officer since March 2021. Prior to joining Cytokinetics, Andrew was at Pfizer and Wyeth Pharmaceuticals for over 20 years with roles of increasing responsibility overseeing US and International pharmaceutical franchises, most recently as Regional President and General Manager North America, Upjohn Business Unit at Pfizer. Prior to this role and during his 11 years at Pfizer, he held several leadership positions including Vice President U.S. Cardiology&Metabolic Marketing where he led the commercialization of Eliquis in the U.S., Vice President and Head of Inflammation Marketing Europe and Vice President Global Commercial Development Rare Disease. Prior to Pfizer, Mr. Callos spent over 10 years at Wyeth Pharmaceuticals in various roles within Business Planning & Analysis, ultimately serving as AVP Marketing across several products. Mr. Callos started the first seven years of his career as Consulting Manager at Accenture. Mr. Callos holds a B.S. in Commerce and Engineering from Drexel University.- Andrew M. Callos，自2021年3月起担任执行副总裁、首席商务官。在加入Cytokinetics之前，Andrew在辉瑞和惠氏制药公司工作了20多年，担任的职责越来越多，负责监督美国和国际制药特许经营权，最近在辉瑞担任Upjohn业务部门北美区域总裁兼总经理。在担任此职务之前，在辉瑞工作的11年多时间里，他担任过多个领导职务，包括美国心脏病学和代谢营销副总裁，在那里他领导了Eliquis在美国的商业化工作，副总裁兼炎症营销欧洲负责人以及全球商业开发罕见病副总裁。在加入辉瑞之前，Callos先生在惠氏制药工作了10多年，在业务规划与分析领域担任过多个职务，最终担任多个产品的营销副总裁。卡洛斯先生开始了他在埃森哲担任咨询经理职业生涯的前七年。Callos先生拥有德雷克塞尔大学商业和工程学士学位。
- Andrew M. Callos,has served as Executive Vice President, Chief Commercial Officer since March 2021. Prior to joining Cytokinetics, Andrew was at Pfizer and Wyeth Pharmaceuticals for over 20 years with roles of increasing responsibility overseeing US and International pharmaceutical franchises, most recently as Regional President and General Manager North America, Upjohn Business Unit at Pfizer. Prior to this role and during his 11 years at Pfizer, he held several leadership positions including Vice President U.S. Cardiology&Metabolic Marketing where he led the commercialization of Eliquis in the U.S., Vice President and Head of Inflammation Marketing Europe and Vice President Global Commercial Development Rare Disease. Prior to Pfizer, Mr. Callos spent over 10 years at Wyeth Pharmaceuticals in various roles within Business Planning & Analysis, ultimately serving as AVP Marketing across several products. Mr. Callos started the first seven years of his career as Consulting Manager at Accenture. Mr. Callos holds a B.S. in Commerce and Engineering from Drexel University.
- Sung H. Lee
Sung H. Lee，自2015年11月起担任研发执行副总裁。Malik博士于2014年8月至2015年11月担任研发高级副总裁。Malik博士于2012年6月至2014年8月担任Cytokinetics, Incorporated研究和早期开发高级副总裁。他自1998年Cytokinetics, Incorporated成立以来一直任职于Cytokinetics，担任过多种职务，包括2008年3月至2012年6月的生物学副总裁，均专注于构建TERM0心血管和肌肉项目。自2000年以来，马利克博士一直在加州大学旧金山分校的心脏病学部任职，目前担任该学院的临床教授。他还是旧金山退伍军人管理局医疗中心的一名执业介入心脏病专家，已有超过18年的时间。自2022年3月起，Malik博士一直担任Rocket制药公司的董事会成员。Malik博士获得了加州大学伯克利分校的学士学位、加州大学旧金山分校的博士学位和加州大学旧金山分校的医学博士学位。
Sung H. Lee,has served as Executive Vice President of Research and Development since November 2015. Dr. Malik served as Senior Vice President of Research and Development from August 2014 to November 2015. Dr. Malik served as Cytokinetics, Incorporated Senior Vice President of Research and Early Development from June 2012 to August 2014. He has been with Cytokinetics since Cytokinetics, Incorporated inception in 1998, serving in a variety of roles, including Vice President, Biology from March 2008 to June 2012, all focused towards building Cytokinetics, Incorporated cardiovascular and muscle programs. Since 2000, Dr. Malik has held an appointment in the Cardiology Division of the University of California, San Francisco, where he is currently a Clinical Professor. He was also a practicing Interventional Cardiologist at the San Francisco Veterans Administration Medical Center for over 18 years. Since March 2022, Dr. Malik has served on the Board of Directors of Rocket Pharmaceuticals, Inc. Dr. Malik received a B.S. from the University of California at Berkeley, a Ph.D. from the University of California at San Francisco and his M.D. from the University of California at San Francisco.- Sung H. Lee，自2015年11月起担任研发执行副总裁。Malik博士于2014年8月至2015年11月担任研发高级副总裁。Malik博士于2012年6月至2014年8月担任Cytokinetics, Incorporated研究和早期开发高级副总裁。他自1998年Cytokinetics, Incorporated成立以来一直任职于Cytokinetics，担任过多种职务，包括2008年3月至2012年6月的生物学副总裁，均专注于构建TERM0心血管和肌肉项目。自2000年以来，马利克博士一直在加州大学旧金山分校的心脏病学部任职，目前担任该学院的临床教授。他还是旧金山退伍军人管理局医疗中心的一名执业介入心脏病专家，已有超过18年的时间。自2022年3月起，Malik博士一直担任Rocket制药公司的董事会成员。Malik博士获得了加州大学伯克利分校的学士学位、加州大学旧金山分校的博士学位和加州大学旧金山分校的医学博士学位。
- Sung H. Lee,has served as Executive Vice President of Research and Development since November 2015. Dr. Malik served as Senior Vice President of Research and Development from August 2014 to November 2015. Dr. Malik served as Cytokinetics, Incorporated Senior Vice President of Research and Early Development from June 2012 to August 2014. He has been with Cytokinetics since Cytokinetics, Incorporated inception in 1998, serving in a variety of roles, including Vice President, Biology from March 2008 to June 2012, all focused towards building Cytokinetics, Incorporated cardiovascular and muscle programs. Since 2000, Dr. Malik has held an appointment in the Cardiology Division of the University of California, San Francisco, where he is currently a Clinical Professor. He was also a practicing Interventional Cardiologist at the San Francisco Veterans Administration Medical Center for over 18 years. Since March 2022, Dr. Malik has served on the Board of Directors of Rocket Pharmaceuticals, Inc. Dr. Malik received a B.S. from the University of California at Berkeley, a Ph.D. from the University of California at San Francisco and his M.D. from the University of California at San Francisco.
- Robert I. Blum
Robert I. Blum于2018年9月加入Gamida Cell Ltd.董事会，担任董事长。Blum先生自2007年1月起担任Cytokinetics公司的总裁兼首席执行官。此前，Blum先生在参与Cytokinetics公司的创立后担任其他职务。加入Cytokinetics公司之前，Blum先生曾在COR Therapeutics公司担任高级业务开发和营销职位，并在Marion Laboratories公司和Syntex公司担任各种商业和业务规划职位。他获得斯坦福大学（Stanford University）人类生物学和经济学学士学位，以及哈佛商学院（Harvard Business School）工商管理硕士学位。
Robert I. Blum,was appointed as President and Chief Executive Officer and as a member of Board of Directors in January 2007. Previous to that appointment, Mr. Blum served as President from February 2006 to January 2007. He served as Executive Vice President, Corporate Development and Commercial Operations and Chief Business Officer from September 2004 to February 2006. From January 2004 to September 2004, he served as Executive Vice President, Corporate Development and Finance and Chief Financial Officer. From October 2001 to December 2003, he served as Cytokinetics, Incorporated Senior Vice President, Corporate Development and Finance and Chief Financial Officer. From July 1998 to September 2001, Mr. Blum was Vice President, Business Development. Prior to joining in July 1998, he was Director, Marketing at COR Therapeutics, Inc. since 1996. From 1991 to 1996, he was Director, Business Development at COR Therapeutics. Prior to that, Mr. Blum performed roles of increasing responsibility in sales, marketing and other pharmaceutical business functions at Marion Laboratories, Inc. and Syntex Corporation. Mr. Blum served as Chairman of the Board of Directors of Gamida Cell Ltd. from September 2018 to March 2023. Mr. Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School.- Robert I. Blum于2018年9月加入Gamida Cell Ltd.董事会，担任董事长。Blum先生自2007年1月起担任Cytokinetics公司的总裁兼首席执行官。此前，Blum先生在参与Cytokinetics公司的创立后担任其他职务。加入Cytokinetics公司之前，Blum先生曾在COR Therapeutics公司担任高级业务开发和营销职位，并在Marion Laboratories公司和Syntex公司担任各种商业和业务规划职位。他获得斯坦福大学（Stanford University）人类生物学和经济学学士学位，以及哈佛商学院（Harvard Business School）工商管理硕士学位。
- Robert I. Blum,was appointed as President and Chief Executive Officer and as a member of Board of Directors in January 2007. Previous to that appointment, Mr. Blum served as President from February 2006 to January 2007. He served as Executive Vice President, Corporate Development and Commercial Operations and Chief Business Officer from September 2004 to February 2006. From January 2004 to September 2004, he served as Executive Vice President, Corporate Development and Finance and Chief Financial Officer. From October 2001 to December 2003, he served as Cytokinetics, Incorporated Senior Vice President, Corporate Development and Finance and Chief Financial Officer. From July 1998 to September 2001, Mr. Blum was Vice President, Business Development. Prior to joining in July 1998, he was Director, Marketing at COR Therapeutics, Inc. since 1996. From 1991 to 1996, he was Director, Business Development at COR Therapeutics. Prior to that, Mr. Blum performed roles of increasing responsibility in sales, marketing and other pharmaceutical business functions at Marion Laboratories, Inc. and Syntex Corporation. Mr. Blum served as Chairman of the Board of Directors of Gamida Cell Ltd. from September 2018 to March 2023. Mr. Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School.
- Fady I. Malik
Fady I. Malik，自2024年5月起担任执行副总裁兼首席财务官。此前，他曾担任Vir Biotechnology， Inc.（一家免疫学公司）的首席财务官（从2023年3月到2024年5月），以及从2021年2月到2023年3月，他曾担任MorphoSys AG（一家生物制药公司）的首席财务官和管理委员会成员。在此之前，从2019年10月到2021年2月，他担任Sangamo Therapeutics， Inc.（生物技术公司）的执行副总裁兼首席财务官。从2005年12月至2019年10月，Lee先生在Gilead Sciences， Inc.（一家生物制药公司）担任各种职务，最近的职位是2019年3月至2019年10月担任财务规划与分析和投资者关系高级副总裁。此前，Lee先生于2018年9月至2019年2月担任财务规划与分析和投资者关系副总裁，2016年6月至2018年8月担任投资者关系副总裁，2013年至2016年5月担任投资者关系高级总监。从2010年到2013年，他担任欧洲财务规划与分析主管，此前从2006年到2010年担任研发财务规划与分析主管。他持有California大学， Irvine的学士学位和Southern California大学的工商管理硕士学位。
Fady I. Malik,has served as Executive Vice President and Chief Financial Officer since May 2024. Previously, Mr. Lee served as the Chief Financial Officer of Vir Biotechnology, Inc., an immunology company from March 2023 to May 2024, and from February 2021 to March 2023, he served as Chief Financial Officer and Management Board member of MorphoSys AG, a biopharmaceutical company. Prior to that, from October 2019 to February 2021, he served as the Executive Vice President and Chief Financial Officer of Sangamo Therapeutics, Inc., a biotechnology company. From December 2005 to October 2019, Mr. Lee served in various roles at Gilead Sciences, Inc., a biopharmaceutical company, most recently as Senior Vice President, Financial Planning&Analysis and Investor Relations from March 2019 to October 2019. Previously, Mr. Lee served as Vice President of Financial Planning & Analysis and Investor Relations from September 2018 to February 2019, Vice President of Investor Relations from June 2016 to August 2018 and Senior Director, Investor Relations from 2013 to May 2016. From 2010 to 2013, Mr. Lee was the Head of Europe Financial Planning&Analysis and prior to that served as the Head of Research & Development Financial Planning & Analysis from 2006 to 2010. Mr. Lee received a B.A. from the University of California, Irvine and an M.B.T. from the University of Southern California.- Fady I. Malik，自2024年5月起担任执行副总裁兼首席财务官。此前，他曾担任Vir Biotechnology， Inc.（一家免疫学公司）的首席财务官（从2023年3月到2024年5月），以及从2021年2月到2023年3月，他曾担任MorphoSys AG（一家生物制药公司）的首席财务官和管理委员会成员。在此之前，从2019年10月到2021年2月，他担任Sangamo Therapeutics， Inc.（生物技术公司）的执行副总裁兼首席财务官。从2005年12月至2019年10月，Lee先生在Gilead Sciences， Inc.（一家生物制药公司）担任各种职务，最近的职位是2019年3月至2019年10月担任财务规划与分析和投资者关系高级副总裁。此前，Lee先生于2018年9月至2019年2月担任财务规划与分析和投资者关系副总裁，2016年6月至2018年8月担任投资者关系副总裁，2013年至2016年5月担任投资者关系高级总监。从2010年到2013年，他担任欧洲财务规划与分析主管，此前从2006年到2010年担任研发财务规划与分析主管。他持有California大学， Irvine的学士学位和Southern California大学的工商管理硕士学位。
- Fady I. Malik,has served as Executive Vice President and Chief Financial Officer since May 2024. Previously, Mr. Lee served as the Chief Financial Officer of Vir Biotechnology, Inc., an immunology company from March 2023 to May 2024, and from February 2021 to March 2023, he served as Chief Financial Officer and Management Board member of MorphoSys AG, a biopharmaceutical company. Prior to that, from October 2019 to February 2021, he served as the Executive Vice President and Chief Financial Officer of Sangamo Therapeutics, Inc., a biotechnology company. From December 2005 to October 2019, Mr. Lee served in various roles at Gilead Sciences, Inc., a biopharmaceutical company, most recently as Senior Vice President, Financial Planning&Analysis and Investor Relations from March 2019 to October 2019. Previously, Mr. Lee served as Vice President of Financial Planning & Analysis and Investor Relations from September 2018 to February 2019, Vice President of Investor Relations from June 2016 to August 2018 and Senior Director, Investor Relations from 2013 to May 2016. From 2010 to 2013, Mr. Lee was the Head of Europe Financial Planning&Analysis and prior to that served as the Head of Research & Development Financial Planning & Analysis from 2006 to 2010. Mr. Lee received a B.A. from the University of California, Irvine and an M.B.T. from the University of Southern California.
- Jeffrey J. Hessekiel
Jeffrey J. Hessekiel, J.D.，2014年2月以来担任执行副总裁兼法律总顾问。从2012年11月到2014年2月，他又担任Arnold & Porter高级顾问的职位，他给新兴增长的和上市的公司在生命科学领域提供建议，在复杂的法律问题与战略事务、医疗合规项目和调查以及监管问题方面。从2012年5月到2012年11月，他还担任Achaogen公司代理总法律顾问，他给相关的临床和政府合同、诉讼管理和就业法的行政事务管理团队提供建议。在Achaogen工作之前，他从2002年12月至2012年5月在Gilead Sciences公司职位的责任也越来越大，最近为合规&质量总监负责Gilead公司企业合规与质量部门的创建和管理。他从1998年10月到2002年11月担任助理的位置，在Wilson Sonsini Goodrich和Rosati PC诉讼和公司事项。从1996年8月到1998年7月，他还担任 Heller Ehrman公司诉讼事项的助理。 加入Heller Ehrman公司之前，他还为一些国际非政府组织工作。他从乔治华盛顿大学（George Washington University）法学院获得法学博士学位，被允许在加州工作。他获得了来自杜克大学（Duke University）政治学学士学位。
Jeffrey J. Hessekiel,has served as Executive Vice President and General Counsel since February 2014, and as Secretary from October 2014 to September 2017, and again from January 2022 to September 2024. From 2012 to 2014, he held the position of Senior Counsel at Arnold& Porter Kaye Scholer LLP, where he advised emerging growth and public companies, primarily in the life sciences sector, on complex legal issues connected with strategic transactions, healthcare compliance programs and investigations, and regulatory matters. Prior to working with Arnold& Porter, from 2002 to 2012, he held positions of increasing responsibility at Gilead Sciences, Inc., most recently as Chief Compliance& Quality Officer where he was responsible for the creation and management of Gilead's Corporate Compliance& Quality department. From 1998 to 2002, Mr.Hessekiel held the position of Associate, working on both litigation and corporate matters for Wilson Sonsini Goodrich and Rosati PC. Mr.Hessekiel also worked as an Associate focusing on litigation matters for Heller Ehrman LLP from 1996 to 1998. Prior to joining Heller Ehrman LLP, Mr.Hessekiel also worked for several international non-governmental organizations. In the not-for-profit sector, Mr. Hessekiel serves as a member of the boards of directors of Biocom California, the association representing the California life science industry, HairToStay, and Life Sciences Cares, Inc. Mr.Hessekiel received his J.D. from The George Washington University Law School and is admitted to practice in California. Mr.Hessekiel received a B.A. in Political Science from Duke University.- Jeffrey J. Hessekiel, J.D.，2014年2月以来担任执行副总裁兼法律总顾问。从2012年11月到2014年2月，他又担任Arnold & Porter高级顾问的职位，他给新兴增长的和上市的公司在生命科学领域提供建议，在复杂的法律问题与战略事务、医疗合规项目和调查以及监管问题方面。从2012年5月到2012年11月，他还担任Achaogen公司代理总法律顾问，他给相关的临床和政府合同、诉讼管理和就业法的行政事务管理团队提供建议。在Achaogen工作之前，他从2002年12月至2012年5月在Gilead Sciences公司职位的责任也越来越大，最近为合规&质量总监负责Gilead公司企业合规与质量部门的创建和管理。他从1998年10月到2002年11月担任助理的位置，在Wilson Sonsini Goodrich和Rosati PC诉讼和公司事项。从1996年8月到1998年7月，他还担任 Heller Ehrman公司诉讼事项的助理。 加入Heller Ehrman公司之前，他还为一些国际非政府组织工作。他从乔治华盛顿大学（George Washington University）法学院获得法学博士学位，被允许在加州工作。他获得了来自杜克大学（Duke University）政治学学士学位。
- Jeffrey J. Hessekiel,has served as Executive Vice President and General Counsel since February 2014, and as Secretary from October 2014 to September 2017, and again from January 2022 to September 2024. From 2012 to 2014, he held the position of Senior Counsel at Arnold& Porter Kaye Scholer LLP, where he advised emerging growth and public companies, primarily in the life sciences sector, on complex legal issues connected with strategic transactions, healthcare compliance programs and investigations, and regulatory matters. Prior to working with Arnold& Porter, from 2002 to 2012, he held positions of increasing responsibility at Gilead Sciences, Inc., most recently as Chief Compliance& Quality Officer where he was responsible for the creation and management of Gilead's Corporate Compliance& Quality department. From 1998 to 2002, Mr.Hessekiel held the position of Associate, working on both litigation and corporate matters for Wilson Sonsini Goodrich and Rosati PC. Mr.Hessekiel also worked as an Associate focusing on litigation matters for Heller Ehrman LLP from 1996 to 1998. Prior to joining Heller Ehrman LLP, Mr.Hessekiel also worked for several international non-governmental organizations. In the not-for-profit sector, Mr. Hessekiel serves as a member of the boards of directors of Biocom California, the association representing the California life science industry, HairToStay, and Life Sciences Cares, Inc. Mr.Hessekiel received his J.D. from The George Washington University Law School and is admitted to practice in California. Mr.Hessekiel received a B.A. in Political Science from Duke University.